Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Event, Webcast

ICON plc to Present at Evercore ISI 2nd Annual HealthCONx Conference


ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019. The presentation will be webcast live from 2pm EST.

A link to the live webcast will be available via the Investor section of our website under "Events".

About ICON plc

ICON plc is a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently operates from 99 locations in 40 countries and has approximately 14,600 employees as at September 30, 2019. Further information is available at www.iconplc.com.

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.

ICON/ICLR-G


These press releases may also interest you

at 02:55
SES announced today that O3b mPOWER, its second-generation software-enabled satellite system, is now operational and can provide high-performance connectivity services around the globe. With the first six O3b mPOWER satellites operating at medium...

at 02:45
Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the first quarter of fiscal year 2024....

at 02:41
EQT AB (publ) today announced that the Nomination Committee proposes Richa Goswami as new Board member in EQT AB, bringing experience and expert knowledge within Brand & Marketing. Richa Goswami has in-depth knowledge and multi-sector experience...

at 02:40
Conditions for participation Shareholders may choose to participate in, and vote at, the Meeting in person or in advance. Shareholders who wish to...

at 02:34
Truecaller, the leading global platform for verifying contacts and blocking unwanted communication, is publishing its interim report for January-March on Tuesday 7 May 2024 at 07.30 CET.  Alan Mamedi, CEO and Odd Bolin, CFO presents the report and...

at 02:33
First quarter 2024 Total revenue was GBP 307.7 (306.4) million, in line with the first quarter of 2023.Gross winnings revenue (B2C) was GBP 297.6 (297.3) million.Underlying EBITDA increased by 20 per cent to GBP 59.3 (49.4) million.Profit before tax...



News published on and distributed by: